Skip to content
OpenCapital
Get started

Ionis Pharmaceuticals IONS Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1

Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 at other companies

Accenture logo
AccentureACN
$462.14M-7.2%
ACR
ACRES Commercial RealtyACR
$540K-33.7%
EMCOR Group logo
EMCOR GroupEME
$5.15M+3.1%
Hyatt Hotels logo
Hyatt HotelsH
$9M+28.6%
EFC
Ellington Financial Inc.EFC
$910.5K+24.0%
Popular logo
PopularBPOP
——

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's sharebased compensation arrangement by sharebased payment award compensation cost1.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's sharebased compensation arrangement by sharebased payment award compensation cost1?
Ionis Pharmaceuticals (IONS) reported sharebased compensation arrangement by sharebased payment award compensation cost1 of $43.29M in Q1 2026.
How has Ionis Pharmaceuticals's sharebased compensation arrangement by sharebased payment award compensation cost1 changed year-over-year?
Ionis Pharmaceuticals's sharebased compensation arrangement by sharebased payment award compensation cost1 increased by 43.3% year-over-year, from $30.21M to $43.29M.
What is the long-term trend for Ionis Pharmaceuticals's sharebased compensation arrangement by sharebased payment award compensation cost1?
Over 2 years (2023 to 2025), Ionis Pharmaceuticals's sharebased compensation arrangement by sharebased payment award compensation cost1 has grown at a 13.2% compound annual growth rate (CAGR), from $105.81M to $135.66M.
What does sharebased compensation arrangement by sharebased payment award compensation cost1 mean?
The total accounting cost of equity-based compensation provided to employees.
How do you interpret sharebased compensation arrangement by sharebased payment award compensation cost1?
Higher levels indicate significant use of equity for retention, which may dilute shareholders but preserves cash.
How does sharebased compensation arrangement by sharebased payment award compensation cost1 compare across companies?
Standard across all public companies; high levels are typical in growth-stage biotech and technology firms.